We found that PCLO (piccolo presynaptic cytomatrix protein), PIM1, CD79B and MYD88 (genes involved in the NF-κB signaling pathway), LRP1B and TP53 (tumor suppressive genes), as well as KMT2D and HIST1H1E (histone modifying genes) were the most commonly mutated genes in the 169 newly diagnosed DLBCL patients. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.